Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think the time is ripe to get out of here!
Very grateful!
nice ride
Any asshole got information and buys?
Last time they were selling... the sons of bitches!
This time they buy !!!!
Anyone who sells under 7 is a jerk!
https://seekingalpha.com/article/4476763-cti-biopharma-long-and-troubled-history-finally-approaching-approval#comments
I find this comment interesting
I am a hematologist at an academic medical center and recently attended(virtually) the Annual Meeting of the American Society of Hematology which took place in Atlanta. I am pleased to report that's the safety issues voiced by Avisol Partners were very well addressed by abstract 3640(Safety Analysis of Pacritinib in Patients with Myelofibrosis and Severe Thrombocytopenia) and abstract 3639( A retrospective Head to head comparison between Pacritinib and Ruxilotinib in patients with Myelofibrosis and moderate to Severe Thrombocytopenia). There are three additional abstracts supportive of the value of pacritinib. The five abstracts are from 15 different major medical centers both in the US and EU, and are co-authored by 25 different hematologists including key opinion leaders in the field of myeloproliferative diseases(the abstracts are available on the company website). During the Meeting several key opinion leaders said they were eagerly awaiting the availability of the drug to treat their patients with severe thrombocytopenia. I am optimistic that pacritinib will be approved by the FDA on February 28, if not sooner. The recent rapid recovery of the share price is consistent with an approval in the near future.
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-december-2021
https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-opinion-yselty_en.pdf
https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-21-24-february-2022-meeting_en.pdf
OBSEVA IS IN DIALOGUE WITH EMA TO UNDERSTAND AREAS THAT MAY REQUIRE FURTHER CLARIFICATION
IMO very large area!
Article 8
1. In order to obtain an authorization to place a medicinal
product on the market regardless of the procedure established
by Regulation (EEC) No 2309/93, an application shall be made
to the competent authority of the Member State concerned.
2. A marketing authorization may only be granted to an
applicant established in the Community.
3. The application shall be accompanied by the following
particulars and documents, submitted in accordance with
Annex I:
(a) Name or corporate name and permanent address of the
applicant and, where applicable, of the manufacturer.
(b) Name of the medicinal product.
(c) Qualitative and quantitative particulars of all the
constituents of the medicinal product in usual terminology,
but excluding empirical chemical formulae, with mention
of the international non-proprietary name recommended
by the World Health Organization where such name exists.
(d) Description of the manufacturing method.
(e) Therapeutic indications, contra-indications and adverse
reactions.
(f) Posology, pharmaceutical form, method and route of
administration and expected shelf life.
(g) If applicable, reasons for any precautionary and safety
measures to be taken for the storage of the medicinal
product, its administration to patients and for the disposal
of waste products, together with an indication of any
potential risks presented by the medicinal product for the
environment.
(h) Description of the control methods employed by the
manufacturer (qualitative and quantitative analysis of the
constituents and of the finished product, special tests, e.g.
sterility tests, tests for the presence of pyrogenic
substances, the presence of heavy metals, stability tests,
biological and toxicity tests, controls carried out at an
intermediate stage of the manufacturing process).
(i) Results of:
physico-chemical, biological or microbiological tests,
toxicological and pharmacological tests, clinical trials.
(j) A summary, in accordance with Article 11, of the product characteristics, one or more specimens or mock-ups of the
outer packaging and the immediate packaging of the
medicinal product, together with a package leaflet.
(k) A document showing that the manufacturer is authorised
in his own country to produce medicinal products.
(l) Copies of any authorisation obtained in another Member
State or in a third country to place the medicinal product
on the market, together with a list of those Member States
in which an application for authorisation submitted in
accordance with this Directive is under examination.
Copies of the summary of the product characteristics
proposed by the applicant in accordance with Article 11
or approved by the competent authorities of the Member
State in accordance with Article 21. Copies of the package
leaflet proposed in accordance with Article 59 or approved
by the competent authorities of the Member State in
accordance with Article 61. Details of any decision to
refuse authorization, whether in the Community or in a
third country, and the reasons for such a decision.
This information shall be updated on a regular basis.
I added 1.13!
Who knows why others are studying? Why do they think it is so important to investigate this molecule?
Maybe JB took a gamble ... but even the FDA isn't joking!
Meanwhile, we wait but the suspicion that the molecule is very good is concrete!
https://clinicaltrials.gov/ct2/show/NCT04858256?cond=Pacritinib&draw=2&rank=1
https://clinicaltrials.gov/ct2/show/NCT04520269?cond=Pacritinib&draw=2&rank=5
https://clinicaltrials.gov/ct2/show/NCT04635059?cond=Pacritinib&draw=2&rank=7
https://clinicaltrials.gov/ct2/show/NCT03645824?cond=Pacritinib&draw=2&rank=8
https://clinicaltrials.gov/ct2/show/NCT02891603?cond=Pacritinib&draw=2&rank=19
instead, I think MDT needs a single door because it's the future and needs to further develop Hugo! Then all this silence on the work done makes too much noise!
Why don't they say goodbye and thank you for what they did?
worry about why
Don't give me too much importance!
Judge with your eyes!
For me they are a continuation of the previous ones! But I didn't have time to understand what...
I thought that once they completed the checking process they got it! why do we have these patents?
Could be others related to Enos? Mmmmm
I'm waiting for the photos!
is it an evolution or a reduction?
it seems like a reduction but it is not logical IMO
Boom boom boom!
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=%22titan+medical%22&OS=%22titan+medical%22&RS=%22titan+medical%22
find the differences
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=%22titan+medical%22&OS=%22titan+medical%22&RS=%22titan+medical%22
how much movement for valentine's day!
with these trading volumes… so the little ones hold!
https://fintel.io/so/us/tmdi
Positive note: the bad news is all out! Another positive note: they have to find the money without fucking the shareholders anymore ... otherwise Perry gets pissed!
Be careful with the energetics ... it depends on which ones! Putin gains from tension, gas and oil skyrocketing! Let's see after the exercises if he like it and leave the troops there ... at this rate the alternative sources will have to be convenient
Psalm 37: 7
the English translation is fanciful
Stand in silence before the Lord and hope in him; do not get irritated by the successful, by the man who plots pitfalls
From Medtronic to Merdtronic it takes a moment
Just think, MDT throws shit on himself by raping TMDI! Are you really sure?
For four pennies, as the shorts say, MDT take the milk and run!
Who knows if others will let MDT in?
not even a poor offer just to show that they did!
Anything!
NOOOOOOOO!!!!!!!!!!!!!!!
and you are believing it???
They are small but They are the right one!
https://www.theramex.com/our-history/
Until we see it above 1 we are in hell!
Titan Medical is developing the Enos™ single access surgical system to provide clinical capabilities that surpass current industry offerings. Through our ongoing engineering efforts, we are working to address the concerns and needs of patients, surgeons and hospitals.
is something boiling in the pot?
Major CDC update - big impact on the title
Due to the lack of rapid tests available, the government will introduce 1 minute self-diagnosis. Put one finger of your right hand in your mouth and one finger of your left hand in your ass. After sixty seconds, You switch fingers. If you feel no taste or smell, isolate yourself!
All payments and milestones were met despite the global pandemic and supply chain constraints across the industry, (bottlenecks)
underscoring the perseverance and commitment of team to further expand its knowledge base in robotic assisted surgery.
(IA or other)
It could mean that something new is coming out... it seems that MDT needs to develop things externally... it seems extremely convenient!
maybe you should cover yourself
TMDI is lucky enough to find itself in a market with enormous potential!
But the value here is determined by speculators!
They have completed the development agreement with MDT! With a little delay but on time! They have proven to be reliable!
A comment from MDT would be nice but obviously they want to buy... and those who despise buy... and sometimes pay dearly!
Maybe MDT should move right now ... as you say!
Then we need to see if the evaluation is adequate
Completion of Product Development and Transfer to Manufacturing
if you look at the timeline you think Memic is far away...
But Enos's eyes can allow the use of artificial intelligence to help the surgeon!
who knows?
PS
I hope they took plenty of time... to surprise us a little! Here everything looks like a bottleneck!
the sooner new patents come out, the last one deserves mention!
It's nice!
I know that many here only appreciate what affects the price!
https://pdfpiw.uspto.gov/.piw?Docid=11234783&homeurl=http%3A%2F%2Fpatft.uspto.gov%2Fnetacgi%2Fnph-Parser%3FSect1%3DPTO2%2526Sect2%3DHITOFF%2526p%3D1%2526u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-bool.html%2526r%3D1%2526f%3DG%2526l%3D50%2526co1%3DAND%2526d%3DPTXT%2526s1%3D%252522titan%252Bmedical%252522%2526OS%3D%252522titan%252Bmedical%252522%2526RS%3D%252522titan%252Bmedical%252522&PageNum=&Rtype=&SectionNum=&idkey=NONE&Input=View+first+page
snakes make movement easier and more natural
they solve problems
http://wpage.unina.it/mario.selvaggio/papers/RAL2018SuturingTool.pdf
Mmmmmmm Mammamia!
LOL
look to the future
If you ask me why speculation comes to mind ...
but I do it simple for my limits ... lol
How can you expect them to put something in it if the toy isn't ready?
no camel no money
It would take someone like Elon Musk to convince your skepticism! and maybe even then you would have to say!
THEN
cover yourself
I believe anyone waiting for the prototype in action! Then you will understand what to do!
I know you are hoping for some obstacles but there is someone who is in a hurry it is a question of the market!
nothing ventured nothing gained
good old days and i even regretted selling them when oppenheimer came out,
then around 2.7 I started charging again
Above 3 there were those who sold like crazy!
The second time it broke through the 3 I gave in! I said it my way... evoking hard memories in Backfermore
I'm now at 40,000 for an average price of 1.7!
Deep red!
I wanted to take back 100,000 but for now I have to diversify!
nice to see how we hold on
Are you covering up?
Don't feel cold! Cover up in time!
MM has also gone very short, have they started covering?
OK at these prices I take a handful!
weeeell were waiiiting
https://titanmedicalinc.com/careers/
you want to see that all positions are covered!
L
O
L
waiting patiently for IDE
I think now they will make it go up!
Go to 3
Feb. 01, 2022 (GLOBE NEWSWIRE) -- ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the appointment of Katja Buhrer as Chief Strategy Officer and member of the company’s Executive Committee, effective February 1, 2022. Ms. Buhrer will oversee a range of operational areas including corporate strategy, investor relations and public relations, and will contribute in other areas such as business development and alliance management.
“We are thrilled to welcome Katja to ObsEva at this important time in the company’s growth,” said Brian O’Callaghan, Chief Executive Officer of ObsEva. “Katja is an accomplished corporate development executive whose track record managing strategic transactions, partnerships, and investor relations programs strengthens our leadership team as we prepare to transition to a commercial-stage company. We further look forward to her leadership as we explore new indications, partnerships, and other strategic opportunities that enhance ObsEva’s value.”
Ms. Buhrer commented, “I am delighted to join ObsEva and collaborate with the executive team to address large, underserved indications that compromise women’s reproductive health. ObsEva’s regulatory, clinical, and strategic advances in the past year, coupled with upcoming catalysts as the company pursues multiple approvals in 2022, make this a compelling opportunity. I look forward to working towards real change in women’s health while enhancing value for our shareholders.”
BOOM!
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=%22titan+medical%22&OS=%22titan+medical%22&RS=%22titan+medical%22
(the red ones matter)
up and down and then up and then down and up and up and down down and up
we're still in hell!
do you think I write so well?
LOL
it's only the answer!
a part